Ironwood Pharma (IRWD) Misses Q3 EPS by 4c; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts IRWD Hot Sheet
Join SI Premium – FREE
Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of $0.28, $0.04 worse than the analyst estimate of $0.32. Revenue for the quarter came in at $108.64 million versus the consensus estimate of $110.15 million.
GUIDANCE:
Ironwood Pharma sees FY2022 revenue of $420-430 million, versus the consensus of $422.7 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- National Bankshares Inc (NKSH) Misses Q3 EPS by 12c
- AppFolio (APPF) Tops Q3 EPS by 3c; Offers Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
